Integration of novel biological targets/biomarkers in the treatment of lethal prostate cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1196225

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Prostate cancer (PC) remains a major cause of cancer-related death. Precision medicine is predicated on the principle of the right drug for the right patient at the right time. This program aims to assess/validate the ability of blood-based molecular markers to predict an individual patient’s response to different treatments and develop new drug strategies based on biological endpoints. Overall, this project has the potential to improve survival and quality of life in men with lethal PC.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Investigator Grants

Funding Amount: $1,930,260.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

clinical studies | drug resistance | lipid metabolism | prostate cancer

Related Links